Vortioxetine for the Treatment of Hoarding Disorder (NCT04035850) | Clinical Trial Compass
WithdrawnPhase 3
Vortioxetine for the Treatment of Hoarding Disorder
Stopped: COVID-19 pandemic
Canada0Started 2019-08-01
Plain-language summary
The present study is a single-group open-label investigation of the potential efficacy of Vortioxetine for treatment of 30 adult volunteers with Hoarding Disorder (HD) (flexible-dose study, with a target dose range 5-25mg). The proposed study will be the first Vortioxetine study in HD, and conducted at the Anxiety Treatment and Research Clinic (ATRC) Canada's largest academic anxiety clinic, a regional referral center for individuals with HD. The study requires a Letter of No Objection from Health Canada and the study will be approved by Hamilton Integrated Research Ethics Board (HiREB).
Who can participate
Age range25 Years ā 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. a principal DSM-5 diagnosis of HD
ā. SI-R score\>=40
ā. age between 25-65
ā. no other antidepressant use in the 4 weeks that precede the first Vortioxetine dose\*
ā. ability to provide written informed consent
Exclusion criteria
ā. current or past diagnosis of mania/hypo-mania, psychotic disorder or a 1st-degree relative with bipolar disorder or a psychotic disorder
ā. past history of behavioural activation or suicidal ideations on antidepressant medication